Citius Pharmaceuticals Inc vs Restaurant Brands International Inc. Common Shares — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Restaurant Brands International Inc. Common Shares trades at $71.01 (market cap $24.56B). The key difference: Restaurant Brands International Inc. Common Shares is far larger — about 1803.2× Citius Pharmaceuticals Inc's market cap, and Restaurant Brands International Inc. Common Shares pays a 3.68% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Restaurant Brands International Inc. Common Shares for 0 Days on average.
| CTXR | QSR | |
|---|---|---|
Market Cap | $13.62M | $24.56B |
Volume | 132,438 | 3,480,368 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $81.67 |
52-Week Low | $0.48 | $65.69 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $3.79M | $39.17B |
Dividend Yield | — | 3.68% |
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →Restaurant Brands International owns and franchises quick-service restaurant brands, including Burger King, Tim Hortons, Popeyes, and Firehouse Subs.
Read more on QSR →